Surveillance for endometrial cancer in women receiving tamoxifen

Annals of Internal Medicine

Volumn 131, Issue 2, 1999, Pages 127-135

  Suh Burgmann, Elizabeth J ^a   Goodman, Annekathryn ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; TAMOXIFEN;

BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SCREENING; ECHOGRAPHY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; FEMALE; HIGH RISK PATIENT; HUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; REVIEW; RISK FACTOR; UTERUS BLEEDING;

EID: 0033587616     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-131-2-199907200-00009     Document Type: Review

References (87)

1. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479-84.
2. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1992;339:1-15.
3. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-88.
4. Ferrazzi E, Cartei G, Mattarazzo R, Fiorentino M. Oestrogen-like effect of tamoxifen on vaginal epithelium. Br Med J. 1977;1:1351-2.
5. Kangas L. Agonistic and antagonistic effects of antiestrogens in different target organs. Acta Oncol. 1992;31:143-6.
6. Boccardo F, Bruzzi P, Rubagotti A, Nicolo GU, Rosso R. Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology. 1981;38:281-5.
7. Boccardo F, Guarneri D, Rubagotti A, Casertelli GL, Bentivoglio G, Conte N, et al. Endocrine effects of tamoxifen in postmenopausal breast cancer patients. Tumori. 1984;70:61-8.
8. Turken S, Siris E, Seidin D, Flaster E, Hyman G, Lindsay R. Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst. 1989;81:1086-8.
9. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC Carbone PP, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst. 1990;82:1327-32.
10. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326:852-6.
11. Schapira DV, Kumar NB, Lyman GH. Serum cholesterol reduction with tamoxifen. Breast Cancer Res Treat. 1990;17:3-7.
12. Schwartz LB, Krey L, Demopoulos R, Goldstein SR, Nachtigall LE, Mittal K. Alterations in steroid hormone receptors in the tamoxifen-treated endometrium. Am J Obstet Gynecol. 1997;176(1 Pt 1):129-37.
13. Anzai Y, Holinka CF, Kuramoto H, Gurpide E. Stimulatory effects of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line). Cancer Res. 1989;49:2362-5.
14. Tamoxifen and the uterus and endometrium [Letter]. Lancet. 1989;1:375-6.
15. De Muylder X, Neven P, De Somer M, Van Belle Y, Vanderick G. Endometrial lesions in patients undergoing tamoxifen therapy, Int J Gynaecol Obstet. 1991;36:127-30.
16. Lahti E, Blanco G. Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol. 1993;81(5 R 1):660-4.
17. Malfetano JH. Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol. 1990;39:82-4.
18. Mathew A, Chabon AB, Kabakow B, Drucker M, Hirschman RJ. Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy. N Y State J Med. 1990;90:207-8.
19. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol. 1993;11:485-90.
20. Barakat RR, Wong G, Curtin JP, Vlamis V, Hoskins WJ. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologie features. Gynecol Oncol. 1994;55:164-8.
21. Adami HO, Krusemo UB, Bergkvist L, Persson I, Pettersson B. On the age-dependent association between cancer of the breast and of the endometrium. A nationwide cohort study. Br J Cancer. 1987;55:77-80.
22. Assikis VJ, Neven P, Jordan VC, Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996;32A:1464-76.
23. ACOG committee opinion. Tamoxifen and endometrial cancer. Number 169, February 1996. Committee on Gynecologic Practice. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet, 1996;53:197-9.
24. Cancer Facts and Figures 1998, New York: American Cancer Society; 1998.
25. Wynder EL, Escher GC, Mantel N. An epidemiological investigation of cancer of the endometrium. Cancer. 1966;19:489-520.
26. MacMahon B. Risk factors for endometrial cancer. Gynecol Oncol. 1974;2: 122-9.
27. Parazzini F, La Vecchia C Bocciolone L, Franceschi S. The epidemiology of endometrial cancer. Gynecol Oncol. 1991;41:1-16.
28. Brinton LA, Berman ML, Mortel R. Twiggs LB, Barrett RJ, Wilbanks GD, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol. 1992;167: 1317-25.
29. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85:304-13.
30. Coulam CB, Annegers JF, Kranz JS. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol. 1983;61:403-7.
31. Vasen HF, Watson P, Mecklin JP, Jass JR, Green JS, Nomizu T, et al. The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer. Anticancer Res. 1994;14:1675-8.
32. Meredith RF, Eisert DR, Kaka Z, Hodgson SE, Johnston GA Jr, Boutselis JG. An excess of uterine sarcomas after pelvic irradiation. Cancer. 1986; 58:2003-7.
33. Duska LR, Flynn CF, Chen A, Whall-Strojwas D, Goodman A. Clinical evaluation of atypical glandular cells of undetermined significance on cervical cytology. Obstet Gynecol. 1998;91:278-82.
34. Yancey M, Magelssen D, Demaurez A, Lee RB. Classification of endometrial cells on cervical cytology. Obstet Gynecol. 1990;76:1000-5.
35. Curtis RE, Hoover RN, Kleinerman RA, Harvey EB. Second cancer following cancer of the female genital system in Connecticut, 1935-82. Natl Cancer Inst Monogr. 1985;68:113-37.
36. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol. 1994; 55(3 Pt 2):S4-14.
37. Karlsson B, Granberg S, Wikland M, Ylostalo P, Torvid K, Marsal K, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding - a Nordic multicenter study. Am J Obstet Gynecol. 1995;172:1488-94.
38. Watson P, Vasen HF, Mecklin JP, Jarvinen H, Lynch HT. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med. 1994;96:516-20.
39. Burke W, Petersen G, Lynch P, Botkin J, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA. 1997;277:915-9.
40. Fornander T, Rutqvist LE, Cedermark B. Glas U, Mattsson A, Silfversward C, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet. 1989;2:117-20.
41. Andersson M, Storm HH, Mouridsen HT. Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncol. 1992;31:259-63.
42. Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst. 1991;83:1013-7.
43. Ryden S, Ferno M, Moller T, Aspegren K, Bergljung L, Killander D, et al. Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Breast Cancer Trial. Acta Oncol. 1992;31:271-4.
44. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fomander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst. 1995;87:645-51.
45. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, et al. Adjuvant tamoxifen in early-stage breast cancer: effects on intercurrent morbidity and mortality. J Clin Oncol. 1991;9:1740-8.
46. MacMahon B. Overview of studies on endometrial cancer and other types of cancer in humans: Perspectives of an epidemiologist. Semin Oncol. 1997;24 (1 Suppl 1):S1-122-S1-39.
47. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86:527-37.
48. Curtis RE, Boice JD Jr, Shriner DA, Hankey BF, Fraumeni JF Jr. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst. 1996;88:832-4.
49. Katase K, Sugiyama Y, Hasumi K, Yoshimoto M, Kasumi F. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma. Cancer. 1998;82:1698-703.
50. Boccardo F, Rubagotti A, Bruzzi P, Cappellini M, Isola G, Nenci I, et al. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group. J Clin Oncol. 1990;8:1310-20.
51. Ribeiro G, Swindell R. The Christie hospital adjuvant tamoxifen trial - status at 10 years. Br J Cancer. 1988;57:601-3.
52. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet. 1987;2:171-5.
53. Stewart HJ. The Scottish trial of adjuvant tamoxifen in node-negative breast cancel. Scottish Cancer Trials Breast Group. J Natl Cancer Inst Monogr. 1992; (11):117-20.
54. Powles TJ, Jones AL, Ashley SE, O'Brien ME. Tidy VA. Treleavan J, et al. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat. 1994;31:73-82.
55. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation. Br J Cancer. 1988; 57:608-11.
56. Hardell L. Tamoxifen as a risk factor for endometrial cancer [Letter]. Cancer. 1990;66:1661-6.
57. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994;343:448-52.
58. Cook LS, Weiss NS, Schwartz SM, White E. McKnight B, Moore DE, et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst. 1995;87:1359-64.
59. Cuenca RE, Giachino J, Arredondo MA, Hempling R, Edge SB. Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use. Cancer. 1996;77:2058-63.
60. Robinson DC, Bloss JD, Schiano MA. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Gynecol Oncol. 1995-59: 186-90.
61. Seoud MA, Johnson J, Weed JC Jr. Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol. 1993;82:165-9.
62. Koss LG, Schreiber K, Oberlander SG, Moussouris HF, Lesser M. Detection of endometrial carcinoma and hyperplasia in asymptomatic women. Obstet Gynecol. 1984;64:1-11.
63. Cecchini S, Ciatto S, Bonardi R, Mazzotta A, Grazzini G, Pacini P, et al. Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen. Gynecol Oncol. 1996;60: 409-11.
64. Cohen I, Altaras MM, Shapira J, Tepper R, Cordoba M, Figer A, et al. Different coexisting endometrial histological features in asymptomatic postmenopausal breast cancer patients treated with tamoxifen. Gynecol Obstet Invest. 1997;43:60-3.
65. Marconi D, Exacoustos C, Cangi B, Perroni A, Zupi E, Valli E, et al. Transvaginal sonographic and hysteroscopic findings in postmenopausal women receiving tamoxifen. J Am Assoc Gynecol Laparosc. 1997;4:331-9.
66. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, et al. Effects of tamoxifen on the uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet. 1994;343: 1318-21.
67. Cohen I, Rosen DJ, Tepper R, Cordoba M, Shapira Y, Altaras MM, et al. Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med. 1993;12:275-80.
68. Bertelli G, Venturini M, Del Mastro L, Garrone O, Cosso M, Gustavino C, et al. Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res Treat. 1998;47:41-6.
69. Hann LE, Giess CS, Bach AM, Tao Y, Baum HJ, Barakat RR. Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings. AJR Am J Roentgenol. 1997;168:657-61.
70. Achiron R. Lipitz S, Sivan E, Goldenberg M, Horovitz A, Frenkel Y, et al. Changes mimicking endometrial neoplasia in postmenopausal, tamoxifentreated women with breast cancer: a transvaginal Doppler study. Ultrasound Obstet Gynecol. 1995;6:116-20.
71. Goldstein SR. Unusual Ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol. 1994;170:447-51.
72. Bornstein J, Auslender R, Pascal B, Gutterman E, Isakov D, Abramovici H. Diagnostic pitfalls of ultrasonographic uterine screening in women treated with tamoxifen. J Reprod Med. 1994;39:674-8.
73. Decensi A, Fontana V, Bruno S, Gustavino C, Gatteschi B, Costa A. Effect of tamoxifen on endometrial proliferation. J Clin Oncol. 1996;14:434-40.
74. Cheng WF, Lin HH, Torng PL, Huang SC. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol. 1997;66: 233-7.
75. Achiron R, Lipitz S, Sivan E, Goldenberg M, Mashiach S. Sonohysterography for Ultrasonographic evaluation of tamoxifen-assodated cystic thickened endometrium. J Ultrasound Med. 1995;14:685-8.
76. Schwartz LB, Snyder J, Horan C, Forges RF. Nachtigall LE, Goldstein SR. The use of transvaginal ultrasound and saline infusion sonohysterography for the evaluation of asymptomatic postmenopausal breast cancer patients on tamoxifen. Ultrasound Obstet Gynecol. 1998;11:48-53.
77. Tepper R, Beyth Y, Altaras MM, Zalel Y, Shapira J, Cordoba M, et al. Value of sonohysterography in asymptomatic postmenopausal tamoxifentreated patients. Gynecol Oncol. 1997;64:386-91.
78. Bonilla-Musoles F, Raga F, Osborne NG, Blanes J. Coelho F. Three-dimensional hysterosonography for the study of endometrial tumors: comparison with conventional transvaginal sonography, hysterosalpingography, and hysteroscopy. Gynecol Oncol. 1997;65:245-52.
79. Exacoustos C, Zupi E, Cangi B, Chiaretti M, Arduini D, Romanini C. Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: an ultrasound, color flow Doppler, hysteroscopic and histological study. Ultrasound Obstet Gynecol. 1995;6:435-42.
80. Kurjak A, Shalan H, Sosic A, Benic S, Zudenigo D. Kupesic S, et al. Endometrial carcinoma in postmenopausal women: evaluation by transvaginal color Doppler ultrasonography. Am J Obstet Gynecol. 1993;169:1597-603.
81. Tepper R, Cohen I, Altaras M, Shapira J, Corboda M, Dror Y, et al. Doppler flow evaluation of pathologic endometrial conditions in postmenopausal breast cancer patients treated with tamoxifen. J Ultrasound Med. 1994;13:635-40.
82. Timmerman D, Deprest J, Bourne T, Van den Berghe I, Collins WP, Vergote I. A randomized trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in postmenopausal patients with breast cancer who were treated with tamoxifen. Am J Obstet Gynecol. 1998;179:62-70.
83. Saldi MH, Sadler RK. Theis VD, Akright BD, Farhart SA, Villanueva GR. Comparison of sonography, sonohysterography, and hysteroscopy for evaluation of abnormal uterine bleeding. J Ultrasound Med. 1997;16:587-91.
84. Berliere M, Charles A, Galant C, Donnez J. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol. 1998;91:40-4.
85. Peterson WF, Novak ER. Endometrial polyps. Obstet Gynecol. 1956;8: 40-7.
86. Armenia CS. Sequential relationship between endometrial polyps and carcinoma of the endometrium. Obstet Gynecol. 1967;30:524-9.
87. Chang J, Powles TJ, Ashley SE, Iveson T, Gregory RK, Dowsett M. Variation in endometrial thickening in women with amenorrhea on tamoxifen. Breast Cancer Res Treat. 1998;48:81-5.